Brussels: When negotiators from the Council and the European Parliament closed their provisional deal on the Critical Medicines Act on 12 May, they were doing something the bloc has resisted for most of its single-market history: writing industrial policy into the heart of its health system. The agreement, which still needs formal confirmation by both institutions, treats the steady supply of antibiotics, insulin, painkillers and other essentials not as a commercial matter best left to manufacturers, but as a question of strategic resilience comparable to energy or semiconductors.
The logic is rooted in a hard number. The Union list of critical medicines now runs to more than two hundred active substances judged indispensable to healthcare systems, and for a large share of them the production of active pharmaceutical ingredients has migrated to a handful of plants outside Europe, concentrated heavily in Asia. A single contaminated batch, an export restriction or a factory fire can ripple across the continent within weeks, as recurring winter shortages of common antibiotics have demonstrated. The new law tries to attack that fragility from several directions at once rather than relying on emergency stockpiles alone.
The most consequential instrument is procurement. Public buyers, which dominate European pharmaceutical demand through national health services, will be required to apply resilience criteria when they tender for critical medicines, rather than awarding contracts to the lowest bid by default. In practice that means a supplier able to demonstrate diversified sourcing or European manufacturing can win business it would have lost on price alone. It is a quiet but significant departure, because for two decades relentless cost competition is precisely what drove production offshore and squeezed margins until many older generics became unprofitable to make.
A second lever lowers the barrier to acting together. Under the agreed text, the number of member states needed to trigger a joint Commission-backed procurement falls from nine to five, making collective purchasing easier to assemble for smaller countries that lack the market weight to negotiate alone. The reform also opens the door to incentives for building or expanding manufacturing capacity for critical medicines and their ingredients inside the Union, alongside measures to diversify supply chains toward a wider set of partners.
What the research community will be watching is whether these tools are strong enough to overcome the economics that created the problem. Reshoring active-ingredient production is expensive, and Europe’s environmental and labour standards mean domestically made molecules will rarely be the cheapest on the market. Resilience requirements in tenders can correct for that only if buyers are willing to pay the premium consistently, year after year, rather than reverting to price discipline once a shortage scare has faded. The law nudges, but it does not compel governments to fund the gap.
There is also a sequencing question. The Critical Medicines Act sits alongside the broader pharmaceutical package agreed in December, which overhauls market authorisation, shortens the European Medicines Agency’s review timelines and rebalances the incentives around data protection and antimicrobial resistance. Together they represent the most far-reaching revision of European medicines policy in more than twenty years. Whether the two reforms reinforce each other or pull in different directions, with one prizing affordability and the other security, will only become clear as national governments transpose them.
The deeper significance is conceptual. For most of its existence the single market treated medicines as tradeable goods whose availability the market would guarantee. The pandemic, followed by repeated shortages of unglamorous off-patent drugs, shattered that assumption. By embedding security of supply into procurement rules and joint purchasing, the Union is conceding that some markets do not self-correct fast enough when lives are at stake. The Critical Medicines Act is a bet that a carefully designed set of obligations and incentives can rebuild a manufacturing base that pure competition dismantled. The evidence for whether that bet pays off will not arrive in headlines but in the dull statistics of shortage notifications over the coming winters.
